The PGY2 Oncology Pharmacy Residency Program at MMC is a 12-month, advanced training program designed to transition PGY1 pharmacy practice residency graduates from general practice to a specialized practice focused on the care of patients with cancer. The program has an emphasis on supportive care, antineoplastic pharmacology, management of malignant and hematological disorders, investigational cancer therapies, and antineoplastic toxicity management.
We aim to customize each resident’s learning experience to meet their needs. During training, residents become part of a patient’s multidisciplinary oncology healthcare team in both inpatient and outpatient settings. Our dedicated preceptors work closely with residents and are committed to ensuring success in a collegial and welcoming environment. Learn more about our preceptors.
In addition to unparalleled training, Maine Medical Center is situated in picturesque Portland, Maine. This community and region offers residents ample opportunities to enjoy life outside of work. Whether it be outdoor activities, arts and culture or food, all is easily accessible to recharge from the stresses of work.
Our PGY2 Oncology Residency Program will exceed expectations with our diverse learning experience whether the goal is direct patient care, enhancing clinical trial knowledge or teaching skills. Graduating residents will be set up for success in their future career as well-rounded, knowledgeable, and compassionate Clinical Oncology Pharmacists.
- Residents receive guidance throughout the process from mentor(s)
- Residents have opportunity to participate in the HOPA Annual meeting poster presentation
- Below are some examples of recent PGY2 Oncology Pharmacy Residency research projects:
- Evaluation of High Dose Methotrexate (HD MTX) Induced Toxicities in Oncology Patients at Maine Medical Center: A Pilot Study
- Adherence to Oral Chemotherapy Safety Standards: A Retrospective Review
- Impact of a Pharmacist Managing Outpatient Oral Oncolytics
- Evaluation of Invasive Fungal Infections and Antifungal Use in High-Risk Oncology Patients
- Evaluation of Etoposide Toxicity and Dosage Adjustments in Hepatic Impairment
- Efficacy of a Moderate Antiemetic Regimen in Gynecologic Cancer Patients Receiving Carboplatin Dosed with an AUC ≥ 4
Our curriculum is deeply rooted in foundational experiences within oncology including a diverse mixture of acute care and ambulatory experiences. Every year our curriculum is customized to the interests and needs of the resident. The program director and preceptors will work with the resident to optimize and adjust the program and learning experiences. Please refer to our manual for more information on learning experiences.
Contact our Program Director
Dorothy Wang, PharmD, BCOP
PGY2 Pharmacy Residency Virtual Open House
November 29, 2023 from 6-7pm EST
- Ambulatory Care
- Critical Care
- Infectious Disease